Blockade of downstream signaling pathways such as RAF/MEK or PI3K/AKT/mTOR in KRAS-mutant cancer [17] and antiangiogenic-based therapy in TP53-mutant cancer would be appropriate therapeutic strategies [18, 19]. The gene discussed is KRAS; the disease is cancer.